Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Overview: A global developer, manufacturer, and marketer of specialized scientific instruments and apparatus for life science research (ADMET screening and molecular biology). The company operates primarily through its "Apparatus and Instrumentation" continuing operations. In July 2005, the company announced plans to divest its "Capital Equipment Business" segment, which is now reported as a discontinued operation. The company anticipates selling this segment in the first half of 2007.
Key Financial Metrics (Year Ended Dec 31, 2006)
| Metric | 2006 Value | 2005 Value |
|---|---|---|
| Total Revenues | $76.2 million | $67.4 million |
| Gross Profit | $38.1 million | $33.3 million |
| Gross Margin | 50.0% | 49.3% |
| Operating Income (Continuing Ops) | $8.7 million | $7.9 million |
| Net Income (Loss) | $(2.3) million | $(31.9) million |
| Net Income from Continuing Ops | $6.6 million | $6.2 million |
| Loss from Discontinued Ops (Net of Tax) | $(9.0) million | $(38.1) million |
| Cash and Cash Equivalents | $9.4 million | $7.6 million |
| Working Capital | $38.6 million | $42.4 million |
| Long-Term Debt | $3.0 million | $8.5 million |
| Stockholders' Equity | $71.9 million | $68.4 million |
Cash Flow: Net cash provided by operating activities was $8.4 million in 2006, compared to $5.2 million in 2005. Net cash used in investing activities was $3.8 million, primarily due to the acquisition of Anthos assets ($1.1 million) and capital expenditures ($2.2 million).
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 13.0% to $76.2 million, driven by demand for core physiology and cell biology equipment, new spectrophotometer products, and international sales growth (particularly in Europe and Asia Pacific).
- Profitability Improvement: Operating income from continuing operations increased 9.7% to $8.7 million. Gross margin improved to 50.0% due to increased sales volumes and improved product mix.
- Discontinued Operations: The loss from discontinued operations decreased significantly to $9.0 million from $38.1 million in 2005. The 2005 loss included $28.7 million in impairment charges, while 2006 included $3.9 million in impairment charges.
- Debt Reduction: The company repaid $5.5 million on its revolving credit facility, reducing outstanding debt from $8.5 million to $3.0 million.
- Accounting Changes: Adoption of SFAS No. 123(R) resulted in $2.1 million of stock-based compensation expense in 2006 (none in 2005). Adoption of SFAS No. 158 required balance sheet recognition of pension underfunding, reducing equity by $1.6 million.
Guidance, Outlook, and Risks
Outlook and Strategy: Management remains focused on organic growth and "tuck-under" acquisitions within the Apparatus and Instrumentation segment. The company expects its financial resources (cash, operating cash flow, and debt capacity) to be sufficient for operations for at least 12 months. Proceeds from the planned sale of the Capital Equipment Business are intended to prepay debt or fund acquisitions.
Key Risks and Contingencies:
- Divestiture Timeline: The sale of the Capital Equipment Business must be completed by March 31, 2007, to avoid triggering a default under the credit facility. Failure to sell or obtain lender consent could accelerate debt repayment.
- Customer Concentration: GE Healthcare accounted for approximately 19% of total revenues in 2006. The distribution agreement with GE Healthcare is extended through March 31, 2007, with negotiations ongoing for a new agreement.
- Foreign Currency: Approximately 53% of revenues are derived from non-U.S. operations. Fluctuations in exchange rates (particularly the U.S. dollar vs. Euro and British Pound) impact reported results.
- Goodwill and Intangibles: Continuing operations hold $34.4 million in goodwill and intangible assets (36% of total assets). Future impairments could adversely affect net income.
Investor Verification Checklist
- Divestiture Status: Verify the progress of the Capital Equipment Business sale and confirm the March 31, 2007 deadline is met to prevent credit facility default.
- GE Healthcare Agreement: Monitor the status of the new distribution agreement with GE Healthcare, given its 19% revenue contribution.
- Stock-Based Compensation: Review the impact of SFAS No. 123(R) on future operating expenses, as $2.1 million was recognized in 2006.
- Impairment Charges: Assess the remaining carrying value of the Capital Equipment Business assets held for sale ($17.3 million) for potential further write-downs prior to sale.
- Debt Covenants: Confirm continued compliance with financial covenants (income, debt coverage, working capital) under the amended $20 million credit facility.